Biocon stock | 2026 forecast, price target & growth

Biocon

NSEI:BIOCON

Rp 379,65

Rp0,00 (0,00%)

379,65 Rp

Rp0,00 (0,00%)

End-of-day quote: 03/27/2026

Biocon Stock Value

The analyst rating for Biocon is currently Outperform.

Outperform

Biocon Company Info

EPS Growth 5Y

5,95%

Market Cap

Rp614,41 B

Long-Term Debt

Rp124,05 B

Quarterly earnings

N/A

Dividend

Rp0,49

Dividend Yield

0,13%

Founded

1978

Industry

Health Care

Country

India

Website

Biocon

ISIN Number

INE376G01013

Website

http://www.biocon.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Rp430,00

13.26%

Last Update: 03/28/2026

Analysts: 19

Highest Price Target Rp580,00

Average Price Target Rp430,00

Lowest Price Target Rp290,00

In the last five quarters, Biocon’s Price Target has risen from Rp305,28 to Rp382,70 - a 25,36% increase. Sixteen analysts predict that Biocon’s share price will increase in the coming year, reaching Rp430,00. This would represent an increase of 13,26%.

Top growth stocks in the health care sector (5Y.)

What does Biocon do?

Biocon Limited operates a biotechnology company that engages in the manufacture of biotechnological products in the pharmaceutical and enzyme sectors through fermentation based technology. Products BIOPHARMACEUTICALS The company manufactures various biopharmaceuticals ranging from small molecules to biologicals and dosage forms Pharmaceutical segment offers therapeutic molecules ranging from small molecules (statins, immunosuppressants) to recombinant proteins (human insulin, vaccines, monoc...

Biocon Limited operates a biotechnology company that engages in the manufacture of biotechnological products in the pharmaceutical and enzyme sectors through fermentation based technology.

Products

BIOPHARMACEUTICALS

The company manufactures various biopharmaceuticals ranging from small molecules to biologicals and dosage forms

Pharmaceutical segment offers therapeutic molecules ranging from small molecules (statins, immunosuppressants) to recombinant proteins (human insulin, vaccines, monoclonal antibodies) derived from microbial and mammalian cell culture-based fermentation technologies in the therapeutic segments, including diabetology, cardiology and oncology.

Small molecules

Small molecules include Anti-Diabetic Agents (Acarbose, Nateglinide, Pioglitazone, Repaglinide, Rosiglitazone); Anti-Hypertensive Agents (Candesartan Cilexitil); Anti-Inflammatory Agents (Serratiopeptidase, Trypsin Chymotrypsin); Anti-Oxidants (Alpha Lipoic Acid, Co-enzyme Q10, L-Carnitine); Cardiovascular Agents (Atorvastatin, Lovastatin, Pravastatin, Simvastatin); Digestive-Aid Enzymes (Bile Extract, Fungal Lactase, Pancreatin, Papain, Pepsin); Hemostatic Agents (Citrus Bioflavinoids, Ethamsylate); Hepatoprotective Agents (L-Ornithine-L-Aspartate); Immunosuppressants (Mycophenolate Mofetil, Tacrolimus);and Neutraceuticals (Carbonyl Iron, Chondroitin Sulphate, Glucosamine Sulphate, Iron Polymaltose Complex, Methyl Sulphonyl Methane).

Statins: Statins are cholesterol-lowering agents used to treat and prevent coronary diseases and are amongst the selling drugs worldwide. The company’s Statins portfolio includes Lovastatin, Simvastatin, Pravastatin, and Atorvastatin.

Immunosuppressants: Immunosuppressants prevent organ and tissue rejection in transplants and require high technology based manufacturing capabilities. Biocon produces Mycophenolate Mofetil (MMF) and tacrolimus on its indigenous fermentation based platform.

Biologicals

In Biologicals the company focuses on products, such as recombinant human insulin, streptokinase, granulocyte stimulating factor (GCSF), human growth hormone (HGH), EPO and Monoclonal Antibodies.

Dosage Forms

The company offers a range of fast moving products in the therapeutic segments of cardiology and diabetes.

Other biopharmaceutical products: The bio-pharmaceutical products include Recombinant Human Insulin, which has completed Phase III clinical trials in India.

ENZYMES

The company manufactures and markets various industrial enzymes, food additives and process aids. It supplies approximately 50 countries across various industry segments, including healthcare, beverage, brewing, baking, fruit juice, starch & alcohol, sugar, animal health, paper & pulp, textiles leather and detergent.

Biocon’s enzymes include Amylases, Amyloglucosidases, Cellulases, Catalase, Lipases, Glucanases, Hemicellulases, Phytases, Proteases, and Pectinases.

Food Additives

Biocon produces a variety of food additives such as emulsifiers, hydrocolloids, natural colours, speciality fats, specialised proteins and improvers for use in the food ingredient, beverage and brewing industries.

Process Aids

Biocon manufactures various process aids such as fining agents and silica or xero gels for use in the food ingredient, beverage and brewing industries.

Fining agents: Fining agents are used in the brewing industry for clarification of beer.

Silica Gels / Xero Gels: Gels act as stabilizers, preventing chill and permanent haze in beer, while imparting flavour, foam and colour to it.

Subsidiaries and Joint ventures

Biocon, Ltd. has entered into an agreement with Innate Pharmaceuticals AB to work jointly on the development of virulent blockers a class of drugs used in the treatment of bacterial diarrhoea.

Syngene International Private Limited: The company’s subsidiary, Syngene, provides chemistry and molecular-based custom research services in early stage drug discovery and development.

Clinigene International Private Limited: The company’s subsidiary, Clinigene, conducts longitudinal research in diabetes and offers various in drug development and clinical trials.

Biocon Biopharmaceuticals Private Limited: The Company is a 51:49 Joint Ventures between the Company and CIMAB S.A. The Company proposes to commercialize the production of monoclonal antibodies and Erythropoietin (EPO) using a specialized Mammalian cell culture technology and Granulocyte Colony Stimulating Factor (GCSF) through bacterial fermentation. The monoclonal antibody is a NBE (New Biological Entity) for the treatment of head and neck cancers and represents a significant initiative in the Company’s foray into original molecules through extensive clinical testing.

In March 2009, Biocon Ltd. opened its new research and development facility, in collaboration with US-based Bristol Myers Squibb, at Biocon Park in Bengaluru. Facility would be dedicated to the discovery and development of new drugs, from initial hit to lead optimisation to early pharmaceutical development to clinical nomination to phase I and phase II clinical studies. The opening up of this facility is an integral part of company's strategy to access top talent around the world and establish a research and development presence in Asia.

Services

Clinical Research

Clinigene is a Clinical Research Organization that offers global biotechnology and pharmaceutical major clinical trial services, regulatory and laboratory capabilities for clinical drug development. Clingene accredited Central Reference Laboratory with clinical specializations in biochemistry, haematology, histopathology and microbiology. Its value-added services include patient registries and clinical databases in diabetes, lipidemia, oncology, cardiovascular diseases.

Custom Research

Syngene is an internationally reputed Custom Research Company (CRC) with multi-disciplinary skills in synthetic chemistry and molecular biology. It conducts high value R&D in early stage drug discovery and development for a diverse global clientele.

Significant Events

Biocon Biopharmaceuticals has formed a joint venture with Cimab, S. A to develop a new antibody drug for treating rheumatoid arthritis (RA) and psoriasis in the United States. The companies are developing the drug, CD 6, which is in phase II of clinical trials.

The company has entered into a strategic partnership with IATRICa, Inc., a biopharmaceutical company, to co-develop a new class of immunoconjugates for targeted immunotherapy of cancers and infectious diseases.

Biocon, Ltd. has a strategic partnership with IATRICa, Inc., to co-develop a class of immunoconjugates for targeted immunotherapy of cancers and infectious diseases. This development would transform the treatment of cancer and infectious diseases. The partnership would also provide treatment for major neoplastic and infectious diseases.

Biocon, Ltd., which partnered the Council of Scientific and Industrial Research (CSIR) institute through a NIMITLI (the New Millennium India Technology Leadership Initiative) project, has developed a recombinant enzyme expression system which has applications in food, cattlefeed and industry.

On September 10, 2009, Amylin Pharmaceuticals, Inc. and Biocon Limited announced that they have entered into an agreement to jointly develop, commercialize and manufacture a peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon would collaborate to develop the therapeutic potential of the compound.

In October 2009, Amylin Pharmaceuticals has signed an agreement with Biocon Limited to jointly develop, commercialize, and manufacture a peptide therapy for the treatment of diabetes.

History

Biocon Limited was founded by Ms. Kiran Mazumdar-Shaw in 1978. The company was formerly known as Biocon India Limited and changed its name to Biocon Limited in 2003.

Biocon Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Sales:** 60% **Biotechnology Sales:** 30% **Research Services:** 10% **TOP 3 Markets:** **India:** 35% **USA:** 25% **Europe:** 20% Biocon Limited generates the majority of its revenue from the pharmaceutical industry, particularly through the production of generics...

At which locations are the company’s products manufactured?

**Production sites of Biocon Limited:** 1. **Bengaluru, India** - Main production facility 2. **Visakhapatnam, India** - Biopharmaceutical production plant 3. **Malaysia** - Insulin production site Biocon Limited is a leading biopharmaceutical company with multiple production sites, primarily loca...

What strategy does Biocon pursue for future growth?

**Focus on Biopharmaceuticals:** Biocon Limited has strongly focused on the development and marketing of biopharmaceuticals. **Expansion into Global Markets:** The company aims to increase its presence in international markets, especially in the USA and Europe. **Partnerships and Collaborations:**...

Which raw materials are imported and from which countries?

**Main raw materials:** Active pharmaceutical ingredients (APIs), Biotechnological materials **Main importing countries:** USA, China, Europe Biocon Limited imports a variety of raw materials necessary for the production of their biopharmaceutical products. These include active pharmaceutical ing...

How strong is the company’s competitive advantage?

**Market share in the biopharma sector:** 5% (estimated for 2025) **R&D expenses:** 12% of revenue (2024) **Product pipeline:** 25 biosimilars in development (2025) Biocon Limited has established itself as a significant player in the biopharma sector, particularly through its strong presenc...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** Approximately 30% (estimated for 2025 based on historical data) **Insider Purchases/Sales:** No significant transactions known in the last 12 months The institutional investor share in Biocon Limited is estimated to be around 30%, based on trends from recent years...

What percentage market share does Biocon have?

**Market share of Biocon Limited:** Estimated 4-5% (based on 2023 data) **Top competitors and their market shares:** 1. **Sun Pharmaceutical Industries Ltd.:** 8-9% 2. **Dr. Reddy's Laboratories Ltd.:** 7-8% 3. **Cipla Ltd.:** 6-7% 4. **Aurobindo Pharma Ltd.:** 5-6% 5. **Lupin Ltd.:** 5-6% 6....

Is Biocon stock currently a good investment?

**Revenue Growth:** 18% (2024) **R&D Expenses:** 12% of revenue (2024) **Market Share in Biosimilar Segment:** 22% (2024) Biocon Limited recorded a revenue growth of 18% in 2024, attributed to strong performance in the biosimilar segment and successful expansion into international markets. The...

Does Biocon pay a dividend – and how reliable is the payout?

**Dividend payment:** No dividend (2025) Biocon Limited has not paid any dividends in recent years. The company is heavily focused on investments in research and development as well as expanding into new markets, which may have influenced the decision not to pay dividends. The reliability of divid...

New support ticket

Explore

Biocon Stock Value

Biocon Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Biocon do?

Biocon Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Biocon Stock Value

Biocon Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Biocon do?

Biocon Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.